About this trial
The CONCORDIA study is a retrospective, observational study evaluating clinical and biochemical outcomes among patients receiving maintenance hemodialysis with medium cut-off (MCO) dialyzers (Theranova) compared with high-flux hemodialysis (HF-HD) and hemodiafiltration (HDF). Using real-world data from non-DOPPS Theranova sites and the DOPPS cohort as an external control, the study aims to assess whether MCO dialyzers are associated with improved outcomes versus HF-HD and non-inferior outcomes compared with HDF. The primary outcome is all-cause mortality, with secondary outcomes including cardiovascular events, hospitalizations, infections, and laboratory measures related to anemia, mineral metabolism, and inflammation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
18 years of age or older
Treated at an in-centre dialysis clinic
Receiving chronic, maintenance HD
Disqualifiers
None
Trial population
Inclusion Criteria * 18 years of age or older * Treated at an in-centre dialysis clinic * Receiving chronic, maintenance HD
Trial design
Other
Retrospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
All Cause Mortality
Death from any cause
All cause mortality
Sponsors and contacts
Click on the lead sponsor to view all of their trials.